THE DEAL, AT A GLANCE
From the announcementMiMARK
01What it doesWhat MiMARK is building: Its lead product, GyLDEC, analyses proteins in uterine fluid collected through a minimally invasive pipelle device.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by DealroomFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedMiMARK raised Seed, announced 2026-08-26From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersMiMARK is using seed funding to bring GyLDEC, an In Vitro Diagnostic for endometrial cancer, to market as an alternative to painful women's health biopsies.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
MiMARK · Financing Record
Explore source-linked visual explanations for MiMARK. Unsupported claims are withheld while source review continues.
Record 11269 · Recorded date: 2026-08-26
Explore company records →